Personalis, Inc. (PSNL)

Market Cap	491.97M
Revenue (ttm)	85.69M
Net Income (ttm)	-84.07M
Shares Out	88.33M
EPS (ttm)	-1.23
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	677,188
Open	5.46
Previous Close	5.39
Day's Range	5.36 - 5.58
52-Week Range	2.81 - 7.79
Beta	1.87
Analysts	Strong Buy
Price Target	8.00 (+43.63%)
Earnings Date	Aug 5, 2025

About ACCD

Personalis, Inc. develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD), therapy response and recurrence monitoring in solid tumor cancers; and ImmunoID NeXT, a tissue-based service that combines whole exome and whole transcriptome sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample....

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Jun 20, 2019
• Employees: 229
• Stock Exchange: NASDAQ
• Ticker Symbol: PSNL
• Website: https://www.personalis.com

Financial Performance

In 2024, Personalis's revenue was $84.61 million, an increase of 15.15% compared to the previous year's $73.48 million. Losses were -$81.28 million, -24.94% less than in 2023.

Analyst Summary

According to 5 analysts, the average rating for PSNL stock is "Strong Buy." The 12-month stock price target is $8.0, which is an increase of 43.63% from the latest price.

Price Target

$8.0

(43.63% upside)

Analyst Consensus: Strong Buy